THERADIAG Announces the Launch of ez-Track1, a Point-of-Care Testing Solution for Therapeutic Drug Monitoring
31 Mai 2022 - 5:45PM
Business Wire
Regulatory News:
THERADIAG (ISIN: FR0004197747, Mnemonic: ALTER), a company
specializing in in vitro diagnostics and theranostics, announces
the launch of ez-Track1, a real Point-of-Care Testing (POCT)
solution for therapeutic drug monitoring.
In search of increasingly patient-focused solutions while
respecting quality standards, the global healthcare sector is
considering more Point-of-Care Testing (POCT), which is becoming a
potential alternative allowing quickly diagnosing a disease,
reducing waiting times and speeding up the start of treatment. As a
company focused on quality innovation, Theradiag is entering this
market with the ez-Track1 system.
Marketed primarily in Europe for the time being under the
Theradiag brand, ez-Track1 carries out tests as close as possible
to patients thanks to whole blood samples (incl. capillary, i.e.
from the fingertips). This ez-Track1 then provides the results of
these tests within 10 minutes. The usage of the system allows
therefore a rapid decision; it will definitively accelerate the
implementation of biotherapies monitoring. Compact, easy to use and
compatible with all the kits developed by Theradiag, the ez-Track1
technological solution completes the Theradiag range of systems
which was until now the Lisa Tracker and the i-Track10.
The system ez-Track1 is CE marked and this will enable a rapid
launch activity. The menu at launch is composed of Infliximab and
anti-Infliximab, as well as Adalimumab, and anti-Adalimumab, all CE
marked. The ez-Track1 test menu related to chronic inflammatory
diseases and other diseases will further expand rapidly.
Bertrand de Castelnau, Chief Executive Officer of Theradiag,
commented: "Six months after the completion of our capital
increase, we are proud to announce the completion of one of our
major projects in our strategic plan: the CE marking of a
technological solution to bring tests closer to patients. Ez-Track1
expands our portfolio of patient solutions and accelerates our
differentiation and our leadership in the biotherapies monitoring
market. I would like to thank all the Theradiag teams for launching
this new technological solution.”
Financial calendar: - H1 2022 revenue, Monday July
18, 2022 - H1 2022 results, Monday September 19, 2022
About Theradiag
Theradiag is the market leader in biotherapy monitoring.
Capitalizing on its expertise in the diagnostics market, the
Company has been developing, manufacturing and marketing innovative
in vitro diagnostic (IVD) tests for over 30 years.
Theradiag pioneered “theranostics” testing (combining therapy
with diagnosis), which measures the efficacy of biotherapy in the
treatment of chronic inflammatory diseases. Going beyond mere
diagnosis, Theranostics aims to help clinicians set up “customized
treatment” for each patient. This method favors the
individualization of treatment, evaluation of its efficacy and the
prevention of drug resistance. In response to this challenge,
Theradiag develops and markets the CE-marked TRACKER® range, a
comprehensive solution of inestimable medical value.
The Company is based in Marne-la-Vallée, near Paris, has
operations in over 70 countries and employs over 60 people. In
2021, the Company posted revenue of €11.1 million. The Theradiag
share is listed on Euronext Growth Paris (ISIN: FR0004197747) and
is eligible for the French PEA-PME personal equity plan. For more
information about Theradiag, please visit our website:
https://www.theradiag.com/
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220531005794/en/
Theradiag Bertrand de Castelnau CEO/Managing Director
Tel.: +33 (0)1 64 62 10 12 contact@theradiag.com
NewCap Financial Communications & Investor Relations
Pierre Laurent / Quentin Massé Tel.: +33 (0)1 44 71 94 94
theradiag@newcap.eu
NewCap Media Relations Nicolas Mérigeau Tel.: +33
(0)1 44 71 94 98 nmerigeau@newcap.fr
Theradiag (EU:ALTER)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Theradiag (EU:ALTER)
Historical Stock Chart
Von Apr 2023 bis Apr 2024